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Background: Human papillomavirus (HPV) is now known to cause a significant proportion of head and
neck cancers (HNC). Qualitative research has shown that some health professionals find it difficult to dis-
cuss HPV with patients due to its sexually transmitted nature, and have concerns about their own knowl-
edge of the virus. We used a survey to quantify attitudes towards discussing HPV among HNC health
professionals.
Methods: We carried out a cross-sectional survey of HNC health professionals (n = 260) in the UK and
Ireland, assessing participants’ knowledge of HPV, their experiences of and attitudes towards discussing
HPV with patients, and their willingness to discuss HPV with their patients in the future.
Results: Overall, health professionals had good knowledge of HPV (mean score: 9.97 out of 12).
Oncologists had significantly greater knowledge than specialist nurses, speech and language therapists
and ‘other’ health professionals. Most were willing to discuss HPV with patients (mean = 4.3 out of 5).
Willingness to discuss HPV in the future was associated with higher HPV knowledge (r = 0.35,
p < 0.001), fewer negative and more positive attitudes towards discussing HPV (r = 0.23 and r = 0.20
respectively, both p < 0.001), fewer personal barriers (r = 0.49, p < 0.001) and greater confidence
(r = 0.58, p < 0.001).
Conclusion: Knowledge, experiences and attitudes to discussing HPV varied across HNC health profes-
sionals. Addressing gaps in health professionals’ HPV knowledge and improving their confidence in dis-
cussing HPV with patients may increase their willingness to have such conversations. This may help
minimise the negative psychosocial consequences of an HPV diagnosis in this patient group.
 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
Overwhelming evidence has demonstrated that human papillo-
mavirus (HPV) plays a causal role in some oropharyngeal squa-
mous cell carcinomas (OSCC) [1], in addition to cervical, anal,
penile, vulva and vaginal cancers [2]. In the US, HPV is detected
in two-thirds of oropharyngeal cancers [3]. Studies have shown
HPV-OSCC is prevalent worldwide and incidence rates are
expected to rise [4], with numbers in the US predicted to exceed
cervical cancer cases by 2020 if the current trend continues [5].
Research has shown both oral sex and open mouth kissing are
associated with acquisition of oral HPV infection [6].
Consistent with findings from the cervical cancer literature
[7,8], studies conducted with head and neck cancer (HNC) health
professionals have identified psychological and communication
challenges associated with the discussion of HPV, primarily dueto its sexually transmitted aetiology [9,10]. In a UK-based study,
some health professionals also expressed concern that their knowl-
edge about the role of HPV in HNC was limited and that this made
it difficult for them to respond to the questions and concerns of
patients [9].
There is wide variation in awareness of the association between
HPV and HNC among health professionals involved in the diagnosis
and treatment of HNC. A recent review [11] has shown that knowl-
edge of the association between HPV and HNC ranges from 26 to
88% in dentists [12,13] and 34 to 91% in other medical profession-
als [14,15]. Variation has also been shown within oral health pro-
fessionals in the US, ranging from a complete lack of knowledge, to
understanding of some details, but none had high levels of knowl-
edge [10]. Participants in the study wanted to improve their
knowledge and have training to aid in communicating with
patients and this may be important in implementing consistent
messages about HPV.
Previous studies suggest that greater knowledge influences
communication related to HPV, for example health professionals
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more likely to recommend the vaccine [16] and self-rated knowl-
edge about HPV vaccination has been shown to be an important
determinant of willingness to recommend the HPV vaccination
among doctors [17]. Some dental professionals say that they need
more information and materials which could help them facilitate
conversations about HPV-OSCC with their patients [10], but this
has not been investigated with HNC health professionals.
This study was carried out in the UK and Ireland, and aimed to
assess knowledge of HPV, experiences, and attitudes to discussing
HPV across different groups of health professionals involved in the
treatment of HNC. We also examined how these factors were asso-
ciated with willingness to discuss HPV with patients in the future.Methods
Participants
Health professionals in roles working directly with HNC
patients (surgeons, oncologists, specialist nurses and allied health
professionals) in the UK or Ireland completed an online or paper
survey. A number of methods of recruitment were used. Profes-
sional organisations (e.g. National Cancer Research Institute,
National Cancer Intelligence Network, NHS Cancer Networks
[18]), and existing contacts in the NHS and from previous research
studies were contacted. Delegate lists from relevant conferences
were used to help provide the names of HNC health professionals
and email addresses were sourced for these names where possible
(n = 246). Health professionals were also recruited at three HNC
conference days where data were collected using paper question-
naires (n = 160). Further information about the methods of recruit-
ment is provided as supplementary material.
We also asked participants who had already taken part in the
study to contact others who they thought might also be eligible
and willing to take part; a technique known as ‘snowballing’
[19]. Where possible, reminders were sent to those who received
the online link to the survey two and four weeks after the initial
email.
Because of this method of recruitment, the response rate is
unknown. The size of the cancer networks and organisations was
unknown and some health professionals may have received the
survey from multiple sources. A sample size calculation with
a = 0.05 and a power of 0.8, suggested that 220 participants were
needed to detect differences in knowledge across the health pro-
fessional groups with a medium effect size of r = 0.3.
Ethical approval
This study was approved by the UCL Research Ethics Commit-
tee, reference 4577/003.
Measures
The survey assessed experience of discussing HPV, knowledge
of HPV, attitudes to discussing HPV and willingness to discuss
HPV in the future. Socio-demographic factors were also assessed.
Most of the items were developed from a previous qualitative
study [9] or previous studies exploring attitudes and knowledge
relating to HPV [7,14]. The survey is included as supplementary
material.
Experience of discussing HPV: Four items assessed health pro-
fessionals’ experiences of informing HNC patients about HPV:
‘Thinking about the patients you treat with HPV-related head
and neck cancer, howmany of them have you told that their cancer
was caused by HPV?’ (all; most; some; none) and ‘If you haveinformed a patient about their HPV status, have you discussed
HPV in detail with a patient?’ (yes; no; not sure). Health profes-
sionals were also asked, ‘If you discuss HPV during consultations,
who usually initiates the discussion?’ (myself; patient; sometimes
me, sometimes the patient; other; not applicable).
Knowledge of HPV: Health professionals were asked ‘Have you
ever heard of HPV?’ (yes; no; don’t know). Health professionals
were also asked to respond ‘true’, ‘false’ or ‘don’t know’ to twelve
knowledge items. Seven of these were from a validated measure
of HPV knowledge [20] and five were specifically about HPV and
HNC (adapted from a previous study [14]). A total score for knowl-
edge was calculated by summing the number of correct responses
to give a maximum possible score of 12 (Cronbach’s a = 0.62).
Twenty-five items assessed health professionals’ attitudes
towards discussing HPV with patients (see supplementary infor-
mation). Responses to these questions were on a 5-point Likert
scale (strongly disagree, disagree, neither agree nor disagree, agree,
strongly agree). These items were developed based on the findings
from the existing literature [7,9,14]. Principal component analysis
(PCA) yielded five factors: confidence in discussing HPV (5 items;
a = 0.89), negative attitudes to discussing HPV (5 items;
a = 0.75), positive attitudes to discussing HPV (5 items; a = 0.76),
personal barriers to discussing HPV (6 items; a = 0.78) and needing
more information (4 items; a = 0.64). Two items in the factor ‘per-
sonal barriers to discussing HPV’ were reverse scored before run-
ning further analysis (see supplementary information).
Participants with missing data on any of the 25 items were
excluded from this analysis (n = 6).
Willingness to discuss HPV in future: Health professionals were
asked, ‘Generally, how willing are you to discuss HPV with your
patients in the future?’ (not at all willing; not very willing; neither
willing or unwilling; somewhat willing; very willing).
Socio-demographic and professional background items
assessed age, sex, profession (surgeon, oncologist, specialist nurse,
speech and language therapist, other), number of years in profes-
sion, whether they had trained in the UK and their main place of
work (hospital, hospice, rehabilitation centre, other). Participants
were also asked, ‘Have you ever looked for any information on
human papillomavirus (HPV) and head and neck cancer?’ and ‘if
yes, where have you looked?’: internet, medical journals, other col-
leagues, conferences, professional organisations, media, other.Analysis
Chi-square tests were used to compare responses to individual
knowledge items across health professional groups and ANOVA
was used to compare total knowledge score between groups.
ANOVA was used to compare each attitudinal factor from the
PCA across health professional groups. Pearson’s correlations were
run to explore the relationships between the attitudinal factors,
willingness to discuss HPV in the future, years practising in their
profession and knowledge. A binary logistic regression was carried
out to investigate the factors that predicted willingness to discuss
HPV in the future (dichotomised for these analyses as ‘not at all’
and ‘not very willing’ versus ‘somewhat’ or ‘very willing’).Results
Sample characteristics
260 health professionals from the UK and Ireland completed the
survey (193 online and 67 on paper). It was not possible to calcu-
late a response rate because an accurate denominator could not be
calculated. Table 1 shows the sample characteristics. The majority
of the sample were female (59.6%, n = 155), had trained in the UK
Table 1
Sample characteristics.
Characteristic Number of participants (n = 260)
Age [median(range)] 45 (21–66)
Sex [n(%)]
Male 105 (40.4)
Female 155 (59.6)
Profession [n(%)]
Surgeon 96 (36.9)
Oncologist 28 (10.8)
Specialist nurse 40 (15.4)
Speech and language therapist 59 (22.7)
Othera 37 (14.2)
Years in profession [median(range)] 17 (0–45)
Trained in the UK [n(%)]
Yes 237 (91.2)
No 23 (8.8)
Main place of work [n(%)]
Hospital 253 (97.3)
Hospice 1 (0.4)
Rehabilitation Centre 1 (0.4)
Other 5 (1.9)
Have you ever heard of HPV [n(%)]
Yes 258 (99.2)
No 1 (0.4)
Don’t know 1 (0.4)
Looked for information on HPV and HNC [n(%)]
Yes 245 (94.2)
No 14 (5.4)
Don’t remember 1 (0.4)
Sources searched for information on HPV and HNC [n(%)]
Internet 205 (78.8)
Medical Journals 191 (73.5)
Other colleagues 183 (70.4)
Conferences 167 (64.2)
Professional organisations 78 (30.0)
Media 53 (20.4)
Study information leaflets 1 (0.4)
Willingness to discuss HPV with patients in the future [n(%)]
Surgeons 86 (91.5)
Oncologists 26 (92.9)
Specialist nurses 35 (87.5)
Speech and language therapists 43 (72.9)
Other 25 (69.4)
a Includes dieticians, radiographers, staff nurses, research nurses.
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Surgeons were the profession most represented in the sample
(36.9%, n = 96) and included head and neck, ear, nose and throat,
oral and maxillofacial surgeons. Oncologists were clinical oncolo-
gists, who in the UK oversee both chemotherapy and radiotherapy.
Some examples of professionals in the ’other’ group of health pro-
fessionals include dieticians, staff nurses, research nurses and
radiographers. The internet, medical journals and other colleagues
were the top three places health professionals looked for informa-
tion about HPV (see Table 2).
The median age of the sample was 45 years (range: 21–66).
Health professionals had worked in their profession for a median
of 17 years (range: 0 to 45 years). Almost all (99.2%) had heard of
HPV.Experience of discussing HPV with patients
Around 75% had previous experience of discussing HPV with a
patient. Surgeons, oncologists and specialist nurses had more
experience of telling their patients that their cancer was caused
by HPV (X2 (12) = 78.49, p < 0.001) and discussing this in detail
with their patients (X2 (8) = 23.48, p = 0.003) than the speechand language therapists (SLTs) or the ‘other’ group of health profes-
sionals. Over two-thirds of oncologists reported initiating the dis-
cussion about HPV themselves (67.9%, n = 19), compared with
54.8% (n = 46) of surgeons and 25.7% (n = 9) of specialist nurses
(X2 (12) = 95.94, p < 0.001). Among SLTs who had discussed HPV
with patients (n = 40), 55.0% (n = 22) reported that the patient
had initiated the discussion.
Knowledge of HPV
The proportion of respondents giving the correct answer to each
individual knowledge item is shown in Table 3. Across all health
professional groups, knowledge of HPV was high. Most knowledge
items were correctly answered by over 75% of participants. Two
items were answered correctly by less than two-thirds of health
professionals: ’HPV usually goes away without needing any treat-
ment’ (45.8% correct) and ‘Most sexually active people will get
HPV at some point in their lives’ (61.9% correct).
The mean knowledge score was 9.97 out of a possible 12. Total
knowledge score was highest in oncologists, followed by surgeons,
then specialist nurses, SLTs and the ‘other’ group of health profes-
sionals (F (4,246) = 10.48, p < 0.001). Surgeons had a significantly
higher mean knowledge score than the ‘other’ group of health pro-
fessionals (p < 0.001) and SLTs (p < 0.001); and oncologists had a
significantly higher mean score than specialist nurses (p = 0.017),
SLTs (p < 0.001) and the ‘other’ group of health professionals
(p < 0.001). Item by item differences across the professional groups
are shown in Table 3.
Attitudes to discussing HPV
Table 4 shows mean scores by professional group for the five
attitude scales. There were significant correlations between many
of these variables ranging in strength from 0.13 to 0.58 (see
Table 5).
Confidence in discussing HPV: The mean (M) score was 3.41
(standard deviation (SD) = 0.83, range 1–5), suggesting overall
health professionals were fairly confident about discussing HPV.
Confidence talking about HPV varied by professional group (F
(4,253) = 22.80, p < 0.001; Table 4) with significantly lower confi-
dence scores for SLTs and health professionals in the ‘other’ group,
compared with surgeons (SLTs p < 0.001; ‘other’ p < 0.001), oncol-
ogists (SLTs p < 0.001; ‘other’ p < 0.001) and specialist nurses (SLTs
p < 0.001; ‘other’ p = 0.036). There was a significant correlation
between confidence and number of years practising in their profes-
sion (r = 0.138, p = 0.027).
Negative attitudes to discussing HPV: In general, negative attitude
scores were low (M = 1.93, SD = 0.53) but there was variation
across the health professional groups (F (4,252) = 3.49, p = 0.009;
Table 4) with significantly higher scores among surgeons, the
‘other’ group of health professionals and SLTs than specialist
nurses (surgeons p = 0.012; ‘other’ p = 0.028; SLTs p = 0.014).
Positive attitudes to discussing HPV: Conversely, positive attitude
scores were high (M = 4.22, SD = 0.49) with similar differences
across professional groups (F (4,254) = 5.59, p < 0.001; Table 4).
Specialist nurses had significantly higher positive attitude scores
than surgeons (p < 0.001), oncologists (p = 0.004) and the ‘other’
health professional group (p = 0.022).
Personal barriers to discussing HPV: The mean score for personal
barriers was 2.87 (SD = 0.69), suggesting some level of disagree-
ment from health professionals about personal barriers to dis-
cussing HPV. When comparing professional groups, a significant
main effect was found (F (4,253) = 8.89, p < 0.001; Table 4), with
surgeons, SLTs and the ‘other’ group reporting significantly higher
scores for barriers than specialist nurses (surgeons p = 0.001; SLTs
p < 0.001; ‘other’ p = 0.003) and surgeons reporting significantly
Table 2
Percentage of each professional group consulting different sources of information about HPV and HNC.
Overall
(n = 260)
Surgeons
(n = 96)
Oncologists
(n = 28)
Specialist nurses
(n = 40)
Speech and language therapists
(n = 59)
Other
(n = 37)
Internet 79% 85% 86% 83% 69% 68%
Medical Journals 74% 86% 96% 63% 59% 57%
Other colleagues 70% 71% 75% 83% 66% 59%
Conferences 64% 80% 82% 45% 54% 46%
Professional
organisations
30% 40% 36% 33% 19% 16%
Media 20% 27% 18% 23% 14% 14%
Study information
leaflets
0.4% 0 0 0 0 3%
NB: Columns do not total 100% because health professionals could consult multiple sources of information.
Table 3
Correct responses (n/%) to individual knowledge of HPV items among all professional groups (n = 260).*
Overall Surgeons Oncologists Specialist
nurses
Speech and language
therapists
Other X2 (p value)
(n = 96) (n = 28) (n = 40) (n = 59) (n = 37)
HPV often has no visible signs or symptoms 239
(91.9)
91 (94.8) 28 (100) 38 (95.0) 49 (83.1) 33
(89.2)
10.66 (0.031)
HPV is very rare (F) 244
(93.8)
94 (97.9) 28 (100) 38 (95.0) 52 (88.1) 32
(86.5)
11.48 (0.022)
A person could have HPV for many years without knowing it 253
(97.7)
95 (99.0) 27 (96.4) 38 (97.4) 56 (94.9) 37
(100)
3.77 (0.438)
Having many sexual partners increases the risk of getting
HPV
230
(88.8)
91 (94.8) 28 (100) 30 (76.9) 49 (83.1) 32
(86.5)
14.69 (0.005)
HPV can cause cervical cancer 253
(97.3)
96 (100) 28 (100) 39 (97.5) 55 (93.2) 35
(94.6)
8.24 (0.083)
HPV usually goes away without needing any treatment 119
(45.8)
47 (49.0) 17 (60.7) 18 (45.0) 25 (42.4) 12
(32.4)
5.85 (0.211)
Most sexually active people will get HPV at some point in
their lives
159
(61.9)
62 (65.3) 21 (75.0) 25 (65.8) 31 (52.5) 20
(54.1)
5.89 (0.207)
HPV can cause oral cancer 240
(92.7)
85 (88.5) 27 (96.4) 38 (97.4) 53 (89.8) 37
(100)
7.92 (0.095)
The oral tongue is the principal head and neck cancer site
associated with HPV (F)
191
(93.7)
83 (86.5) 26 (92.9) 24 (60.0) 39 (66.1) 19
(52.8)
27.15 (<0.001)
HPV is a relatively uncommon sexually transmitted infection
(F)
201
(78.2)
84 (87.5) 27 (96.4) 26 (68.4) 40 (67.8) 24
(66.7)
19.02 (0.001)
HPV is associated with a much improved prognosis for
patients with head and neck cancer
229
(88.1)
87 (90.6) 27 (96.4) 34 (85.0) 53 (89.8) 28
(75.7)
8.41 (0.078)
Most patients with oral HPV experience symptoms of the
infection (F)
223
(85.8)
91 (94.8) 27 (96.4) 34 (85.0) 42 (71.2) 29
(78.4)
20.96 (<0.001)
ANOVA
Total knowledge score: mean (standard deviation) 9.97
(1.82)
10.48ab
(1.32)
11.11cde
(0.83)
9.74
(1.85)c
9.22 (2.06)bd 9.14
(2.2)ae
F (4,246) = 10.48,
p < 0.001
* n varies slightly between items due to missing data; (F) indicates items for which ‘false’ is the correct response. All other items are true; abcde indicates which groups are
significantly different from each other in post hoc tests.
Table 4
Attitudes to discussing HPV with oropharyngeal cancer patients: mean scale scores across health professional groups.
Surgeons Oncologists Specialist nurses Speech and language therapists Other F (p value)
(n = 96) (n = 28) (n = 40) (n = 59) (n = 37)
Confidence talking about HPV 3.74 (0.65)ab 3.88 (0.58)cd 3.59 (0.74)ef 2.74 (0.82)ade 3.10 (0.80)bcf 22.80 (<0.001)
Negative attitudes to discussing HPV 1.98 (0.53)a 1.90 (0.47) 1.66 (0.55)abc 2.00 (0.42)c 2.02 (0.60)b 3.49 (0.009)
Positive attitudes to discussing HPV 4.12 (0.50)a 4.10 (0.46)b 4.52 (0.48)abc 4.26 (0.42) 4.18 (0.48)c 5.59 (<0.001)
Personal barriers to discussing HPV 2.86 (0.66)ab 2.80 (0.69) 2.38 (0.66)acd 3.17 (0.64)bd 2.93 (0.61)c 8.89 (<0.001)
Need for more information 3.69 (0.52)a 3.66 (0.60)b 3.95 (0.38) 4.18 (0.41)abc 3.77 (0.64)c 9.83 (<0.001)
n for items varies slightly due to missing data.
abcdefindicates across rows which groups are significantly different from each other in post hoc tests.
Scores range from 1 to 5; 1 represents low confidence, less negative attitudes, less positive attitudes, fewer personal barriers and less need for information.
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discussing HPV were negatively associated with knowledge
(r = 0.198, p < 0.01) and positively associated with the need for
more information (r = 0.299, p < 0.01).
Needing more information: Mean scores were above the mid-
point (M = 3.85 and SD = 0.54), suggesting health professionals feltthey needed more information about HPV. There were significant
differences between health professional groups (F (4,254) = 9.83,
p < 0.001; Table 4). SLTs had a significantly greater need for infor-
mation than surgeons (p < 0.001), oncologists (p < 0.001) and the
‘other’ group of health professionals (p = 0.002).
Table 5
Correlation matrix for all attitudinal factors, total knowledge score and willingness to discuss HPV.
Confidence in
discussing HPV
Negative attitudes to
discussing HPV
Positive attitudes to
discussing HPV
Personal barriers to
discussing HPV
Need for more
information
Knowledge Willingness to
discuss HPV
Confidence in
discussing HPV
1
Negative attitudes to
discussing HPV
0.097 1
Positive attitudes to
discussing HPV
0.132* 0.508** 1
Personal barriers to
discussing HPV
0.553** 0.231** 0.63** 1
Need for more
information
0.415** 0.213** 0.156* 0.299** 1
Knowledge 0.435** 0.071 0.033 0.198** 0.154* 1
Willingness to
discuss HPV
0.582** 0.232** 0.201** 0.492** 0.149* 0.347** 1
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Willingness to discuss HPV in the future was significantly pos-
itively associated with confidence in discussing HPV (r = 0.582,
p < 0.001), positive attitudes to discussing HPV (r = 0.201,
p < 0.001) and knowledge (r = 0.347, p < 0.001; Table 5). Significant
negative associations were found between willingness to discuss
HPV in the future and negative attitudes to discussing HPV
(r = 0.232, p < 0.001), personal barriers to discussing HPV
(r = 0.492, p < 0.001) and the need for more information
(r = 0.149, p < 0.05).
Multivariate logistic regression showed that confidence dis-
cussing HPV was a significant predictor of willingness to discuss
HPV (adjusted OR = 7.67, 95% CI 1.76–33.44; Table 6), while having
personal barriers to discussing HPV was associated with signifi-
cantly decreased odds of being willing to discuss HPV (OR = 0.13,
95% CI 0.019–0.817). Nagelkerke’s R2 indicates that the predictor
variables explain 49% of the variance in willingness to discuss
HPV in the future.
Discussion
To our knowledge, this is the first quantitative study assessing
knowledge and attitudes about discussing HPV with HNC patients
among health professionals in the UK and Ireland. Almost all had
heard of HPV and most had looked for information about HPV
and HNC. The internet, medical journals and other colleagues were
the top three sources of information, supporting findings from pre-
vious research [10]. Oncologists had the greatest knowledge, fol-
lowed by surgeons, specialist nurses, SLTs and the health
professionals in the ‘other’ group, suggesting a need to increase
knowledge among allied health professionals. The proportion of
surgeons answering the specific HNC questions correctly was
slightly lower than in a previous study with head and neck sur-
geons [14], but knowledge was high in both studies.
Supporting previous research about discussing HPV in the con-
text of the HPV vaccination [16,17], health professionals in this
study with greater knowledge also had greater confidence about
discussing HPV and were more willing to do so in the futureTable 6
Unadjusted and adjusted odds ratios (OR) for factors predicting willingness to discuss HP
Unadjusted OR (95% CI)
Confidence in discussing HPV 8.34 (3.24–21.45)
Personal barriers 0.06 (0.01–0.24)
Negative attitudes to discussing HPV 0.40 (0.11–1.41)
Positive attitudes to discussing HPV 1.86 (0.52–6.75)
More information 0.53 (0.15–1.94)[17]. Factors which had the greatest association with willingness
to discuss HPV in the future were confidence and having low per-
sonal barriers. Health professionals reporting personal barriers to
discussing HPV were less willing to do so, had lower knowledge
of HPV and reported needing more information about HPV. This
study identifies areas which could be targeted to increase health
professionals’ confidence to discuss HPV and also their willingness
to do so. Confidence could be increased by improving knowledge,
meeting information needs, and addressing personal barriers and
negative attitudes towards discussing HPV. This could result in
more health professionals discussing HPV with their patients.
Theories of behaviour change aim to explain why people adopt
new behaviours and what components may be responsible for that
change. The Capability-Opportunity-Motivation Behaviour (COM-
B) model [21] is a way of conceptualising the factors needed for
a particular behaviour to take place, and could be helpful in under-
standing the reasons some health professionals do not discuss HPV
with their HNC patients, and in identifying targets for interven-
tions aimed at facilitating these discussions. Assessing the results
from this study against the components of the COM-B model
shows that surgeons and oncologists have the capability, motiva-
tion and opportunity to discuss HPV, and that they are doing so.
SLTs and other allied health professionals may lack capability
because of lower knowledge and confidence; may lack motivation
because of their lack of confidence; and may lack opportunity
because they are likely to see patients less frequently than sur-
geons and oncologists.
Knowledge was shown to be highest in surgeons and oncolo-
gists, and lowest in SLTs and the ‘other’ group of health profession-
als. Surgeons and oncologists also showed a greater confidence
about discussing HPV than the other health professional groups.
SLTs and health professionals in the ‘other’ group reported more
personal barriers (e.g. embarrassment) to discussing HPV, and
these groups were less willing to discuss HPV. Previous research
in dentists has found confidence in performing oral examinations
or providing advice about risk habits to be directly correlated with
their subsequent performance of oral examinations or provision of
advice to patients [22]. Educational materials could be used in
future interactions which may help increase knowledge and confi-V in the future.
Sig. (p value) Adjusted* OR (95% CI) Sig. (p value)
<0.001 7.67 (1.76–33.44) 0.007
<0.001 0.13 (0.02–0.82) 0.03
0.153 0.34 (0.04–2.84) 0.322
0.342 0.25 (0.02–2.82) 0.263
0.34 5.40 (0.45–64.24) 0.182
72 R.H. Dodd et al. / Oral Oncology 68 (2017) 67–73dence about having these conversations with patients. Didactic
approaches such as information booklets, videos and interactive
lectures have been found to be effective at increasing knowledge
in dentists [23].
Greater proportions of oncologists, surgeons and specialist
nurses than allied health professionals in this sample had told all
or most of their patients that their cancer was caused by HPV,
had discussed HPV in detail with those patients, and were willing
to discuss HPV in the future. These health professionals are ideally
situated to have this discussion with patients as they are likely to
see patients more frequently than allied health professionals. As
there was still a proportion of allied health professionals who
had discussed HPV in detail with these patients, this demonstrates
that it is possible for questions to come up at any point during
patients’ diagnosis, treatment and aftercare, consistent with previ-
ous findings [24]. It is therefore important that all health profes-
sionals caring for these patients feel adequately informed and
motivated, and have the necessary skills to have these discussions
with patients. Further training could be targeted at increasing
these three components in these health professional groups to help
facilitate the discussions of HPV with patients. It is important for
health professionals to have conversations with their patients
about HPV so that information can be delivered by a trustworthy
and reliable source, who can also address concerns and uncertain-
ties around the sexually transmitted nature of HPV.
This study has some limitations. Due to the recruitment meth-
ods used, it was not possible to calculate a response rate and there-
fore it is difficult to assess the representativeness of the sample.
The associations and differences found in this sample are more
likely to be generalisable than the prevalence estimates. The sam-
ple was also self-selected and it is possible that those who were
most interested in HPV were those who took part. Further research
would also be needed to determine whether these results extend
to other countries, beyond the UK and Ireland. As some of the par-
ticipants completed the survey at study days, it is possible that
some of them completed it following the talks given that day
and this could have influenced their responses, perhaps leading
to inflated estimates of knowledge. Although some of the questions
assessing participants’ knowledge were from a validated scale, not
all of the questions were taken from validated scales. Future work
should look at validating a measure assessing knowledge of HPV-
OSCC.Conclusion
This study shows that knowledge and attitudes about HPV-
OSCC varies across health professional groups, with surgeons,
oncologists and specialist nurses having more experience of dis-
cussing HPV-OSCC with their patients. Behaviour change models
could provide useful frameworks for future training and interven-
tions to equip all health professionals with the vital components to
be able to discuss HPV-OSCC with their patients and increase their
willingness to do so.Author’s contributions
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